A candidate protective factor in amyotrophic lateral sclerosis: heterogenous nuclear ribonucleoprotein G.

Bax TAR DNA binding protein 43 TG(SOD1*G93A)1Gur mice amyotrophic lateral sclerosis heterogenous nuclear ribonucleoprotein G heterogenous nuclear ribonucleoprotein G-siRNA neuron death superoxide dismutase 1

Journal

Neural regeneration research
ISSN: 1673-5374
Titre abrégé: Neural Regen Res
Pays: India
ID NLM: 101316351

Informations de publication

Date de publication:
Jul 2023
Historique:
entrez: 26 12 2022
pubmed: 27 12 2022
medline: 27 12 2022
Statut: ppublish

Résumé

Heterogenous nuclear ribonucleoprotein G is down-regulated in the spinal cord of the Tg(SOD1*G93A)1Gur (TG) amyotrophic lateral sclerosis mouse model. However, most studies have only examined heterogenous nuclear ribonucleoprotein G expression in the amyotrophic lateral sclerosis model and heterogenous nuclear ribonucleoprotein G effects in amyotrophic lateral sclerosis pathogenesis such as in apoptosis are unknown. In this study, we studied the potential mechanism of heterogenous nuclear ribonucleoprotein G in neuronal death in the spinal cord of TG and wild-type mice and examined the mechanism by which heterogenous nuclear ribonucleoprotein G induces apoptosis. Heterogenous nuclear ribonucleoprotein G in spinal cord was analyzed using immunohistochemistry and western blotting, and cell proliferation and proteins (TAR DNA binding protein 43, superoxide dismutase 1, and Bax) were detected by the Cell Counting Kit-8 and western blot analysis in heterogenous nuclear ribonucleoprotein G siRNA-transfected PC12 cells. We analyzed heterogenous nuclear ribonucleoprotein G distribution in spinal cord in the amyotrophic lateral sclerosis model at various time points and the expressions of apoptosis and proliferation-related proteins. Heterogenous nuclear ribonucleoprotein G was mainly localized in neurons. Amyotrophic lateral sclerosis mice were examined at three stages: preonset (60-70 days), onset (90-100 days) and progression (120-130 days). The number of heterogenous nuclear ribonucleoprotein G-positive cells was significantly higher in the anterior horn of the lumbar spinal cord segment of TG mice at the preonset stage than that of control group but lower than that of the control group at the onset stage. The number of heterogenous nuclear ribonucleoprotein G-positive cells in both central canal and surrounding gray matter of the whole spinal cord of TG mice at the onset stage was significantly lower than that in the control group, whereas that of the lumbar spinal cord segment of TG mice was significantly higher than that in the control group at preonset stage and significantly lower than that in the control group at the progression stage. The numbers of heterogenous nuclear ribonucleoprotein G-positive cells in the posterior horn of cervical and thoracic segments of TG mice at preonset and progression stages were significantly lower than those in the control group. The expression of heterogenous nuclear ribonucleoprotein G in the cervical spinal cord segment of TG mice was significantly higher than that in the control group at the preonset stage but significantly lower at the progression stage. The expression of heterogenous nuclear ribonucleoprotein G in the thoracic spinal cord segment of TG mice was significantly increased at the preonset stage, significantly decreased at the onset stage, and significantly increased at the progression stage compared with the control group. heterogenous nuclear ribonucleoprotein G expression in the lumbar spinal cord segment of TG mice was significantly lower than that of the control group at the progression stage. After heterogenous nuclear ribonucleoprotein G gene silencing, PC12 cell survival was lower than that of control cells. Both TAR DNA binding protein 43 and Bax expressions were significantly increased in heterogenous nuclear ribonucleoprotein G-silenced cells compared with control cells. Our study suggests that abnormal distribution and expression of heterogenous nuclear ribonucleoprotein G might play a protective effect in amyotrophic lateral sclerosis development via preventing neuronal death by reducing abnormal TAR DNA binding protein 43 generation in the spinal cord.

Identifiants

pubmed: 36571358
pii: NeuralRegenRes_2023_18_7_1527_357916
doi: 10.4103/1673-5374.357916
pmc: PMC10075103
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1527-1534

Déclaration de conflit d'intérêts

None

Références

Nat Med. 2018 Aug;24(8):1136-1142
pubmed: 29942091
Adv Exp Med Biol. 2021;1281:243-267
pubmed: 33433879
PLoS One. 2022 May 16;17(5):e0268159
pubmed: 35576218
Mol Cell Neurosci. 2019 Oct;100:103396
pubmed: 31445085
Nucleic Acids Res. 2022 Apr 22;50(7):3867-3891
pubmed: 35357488
Acta Neuropathol. 2020 Nov;140(5):599-623
pubmed: 32748079
Annu Rev Biochem. 1993;62:289-321
pubmed: 8352591
Cell. 2018 Jul 26;174(3):688-699.e16
pubmed: 29961577
Biochemistry (Mosc). 2019 Mar;84(3):205-219
pubmed: 31221059
Cold Spring Harb Perspect Med. 2017 Nov 1;7(11):
pubmed: 28062558
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Brain Nerve. 2016 Sep;68(9):1081-1086
pubmed: 27667492
Acta Neuropathol Commun. 2021 Mar 24;9(1):52
pubmed: 33762006
Neurochem Res. 2022 Apr;47(4):921-932
pubmed: 35124781
Neurochem Res. 2020 Jul;45(7):1729-1730
pubmed: 32323106
Mol Neurobiol. 2018 Feb;55(2):1323-1337
pubmed: 28124772
Angew Chem Int Ed Engl. 2021 Apr 19;60(17):9215-9246
pubmed: 32144830
Int J Biochem Cell Biol. 2019 Mar;108:1-6
pubmed: 30593955
Cell Stem Cell. 2022 Jun 2;29(6):918-932.e8
pubmed: 35659876
Cytogenet Genome Res. 2002;99(1-4):141-5
pubmed: 12900556
Biomedicines. 2022 Mar 19;10(3):
pubmed: 35327513
Rev Neurol (Paris). 2017 May;173(5):273-279
pubmed: 28449882
Brain Res Bull. 2020 Feb;155:145-154
pubmed: 31846697
Brain. 2018 May 1;141(5):1320-1333
pubmed: 29562314
Handb Clin Neurol. 2018;148:603-623
pubmed: 29478603
PLoS Genet. 2009 Nov;5(11):e1000707
pubmed: 19893608
Nature. 1993 Mar 4;362(6415):59-62
pubmed: 8446170
Mol Neurobiol. 2022 Apr;59(4):2258-2276
pubmed: 35066760
Hum Mol Genet. 2002 Aug 15;11(17):2037-49
pubmed: 12165565
Cold Spring Harb Perspect Med. 2017 Sep 1;7(9):
pubmed: 27920024
Neuron. 2019 Mar 20;101(6):1057-1069
pubmed: 30897357
Nat Commun. 2022 May 19;13(1):2776
pubmed: 35589706
Hum Mol Genet. 2017 Aug 1;26(15):2882-2896
pubmed: 28481984
Acta Neuropathol Commun. 2017 Apr 21;5(1):31
pubmed: 28431575
J Neurochem. 2021 Jul;158(2):119-137
pubmed: 33930186
Nucleic Acids Res. 2009 Jul;37(12):4116-26
pubmed: 19429692
Cell Res. 2019 Mar;29(3):233-247
pubmed: 30728452
Dis Model Mech. 2017 May 1;10(5):537-549
pubmed: 28468939
Nat Neurosci. 2019 Feb;22(2):167-179
pubmed: 30643292
Expert Opin Ther Targets. 2017 Jan;21(1):37-49
pubmed: 27786579
Acta Neuropathol. 2018 Feb;135(2):227-247
pubmed: 29134320
Neurosci Biobehav Rev. 2021 Jan;120:28-47
pubmed: 33171144
Cold Spring Harb Perspect Med. 2018 May 01;8(5):
pubmed: 28270533
Front Mol Biosci. 2021 Apr 12;8:659610
pubmed: 33912591
Front Cell Dev Biol. 2022 Feb 17;10:840256
pubmed: 35372329
Ann Neurol. 2007 May;61(5):427-34
pubmed: 17469116
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Mol Cells. 2018 Sep 30;41(9):818-829
pubmed: 30157547
Elife. 2019 Jan 24;8:
pubmed: 30674417
Hum Genet. 2017 Sep;136(9):1193-1214
pubmed: 28762175
Int J Biol Sci. 2018 Jul 27;14(10):1306-1320
pubmed: 30123078
Nat Neurosci. 2017 Sep;20(9):1225-1235
pubmed: 28714954
Mol Cell Biochem. 2017 Mar;427(1-2):123-131
pubmed: 28000042

Auteurs

Fang Yang (F)

Department of Neurology, Jiangxi Provincial People's Hospital, The Clinical College of Nanchang Medical College, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi Province, China.

Wen-Zhi Chen (WZ)

Department of Neurology, Jiangxi Provincial People's Hospital, The Clinical College of Nanchang Medical College, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi Province, China.

Shi-Shi Jiang (SS)

Department of Neurology, Jiangxi Provincial People's Hospital, The Clinical College of Nanchang Medical College, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi Province, China.

Xiao-Hua Wang (XH)

Department of Geriatrics and General Practice/General Family Medicine, Jiangxi Provincial People's Hospital, The Clinical College of Nanchang Medical College, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi Province, China.

Ren-Shi Xu (RS)

Department of Neurology, Jiangxi Provincial People's Hospital, The Clinical College of Nanchang Medical College, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi Province, China.

Classifications MeSH